Title :

Clinico-biological features and clonal hematopoiesis in patients with severe covid-19

Author(s) :

Duployez, Nicolas [Auteur]
Cancer Heterogeneity, Plasticity and Resistance to Therapies (CANTHER) - UMR 9020 - UMR 1277
Demonchy, Jordane [Auteur]
Cancer Heterogeneity, Plasticity and Resistance to Therapies - UMR 9020 - U 1277 [CANTHER]
Berthon, Celine [Auteur]
Cancer Heterogeneity, Plasticity and Resistance to Therapies (CANTHER) - UMR 9020 - UMR 1277
Miniaturisation pour la Synthèse, l'Analyse et la Protéomique (MSAP) - USR 3290
GOUTAY, Julien [Auteur]
CIC CHU ( Lille)/inserm
Caplan, Morgan [Auteur]
CIC CHU ( Lille)/inserm
Moreau, Anne-Sophie [Auteur]
Centre Hospitalier Régional Universitaire [Lille] [CHRU Lille]
Bignon, Anne [Auteur]
Centre Hospitalier Régional Universitaire [Lille] [CHRU Lille]
Marceau-Renaut, Alice [Auteur]
Cancer Heterogeneity, Plasticity and Resistance to Therapies - UMR 9020 - U 1277 [CANTHER]
Garrigue, Delphine [Auteur]
Centre Hospitalier Régional Universitaire [Lille] [CHRU Lille]
Raczkiewicz, Imelda [Auteur]
Cancer Heterogeneity, Plasticity and Resistance to Therapies - UMR 9020 - U 1277 [CANTHER]
Geffroy, Sandrine [Auteur]
Cancer Heterogeneity, Plasticity and Resistance to Therapies - UMR 9020 - U 1277 [CANTHER]
Bucci, Maxime [Auteur]
Equipe 3 - Facteurs de persistance des cellules leucémique - [INSERM U837]
Alidjinou, Enagnon Kazali [Auteur]
Pathogenèse virale du diabète de type 1 - ULR 3610 [Laboratoire de Virologie]
Demaret, Julie [Auteur]
Institut d'Immunologie [CHRU Lille]
Labalette, Myriam [Auteur]
Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286
Brousseau, Thierry [Auteur]
Institut de Microbiologie [CHRU Lille]
Dupont, Annabelle [Auteur]
Récepteurs nucléaires, Maladies Cardiovasculaires et Diabète (EGID) - U1011
RAUCH, ANTOINE [Auteur]
Récepteurs nucléaires, Maladies Cardiovasculaires et Diabète (EGID) - U1011
Poissy, Julien [Auteur]
Unité de Glycobiologie Structurale et Fonctionnelle (UGSF) - UMR 8576
Susen, Sophie [Auteur]
Récepteurs nucléaires, Maladies Cardiovasculaires et Diabète (EGID) - U1011
Preudhomme, Claude [Auteur]
Cancer Heterogeneity, Plasticity and Resistance to Therapies (CANTHER) - UMR 9020 - UMR 1277
Miniaturisation pour la Synthèse, l'Analyse et la Protéomique (MSAP) - USR 3290
Quesnel, Bruno [Auteur]
Cancer Heterogeneity, Plasticity and Resistance to Therapies (CANTHER) - UMR 9020 - UMR 1277
Miniaturisation pour la Synthèse, l'Analyse et la Protéomique (MSAP) - USR 3290

Journal title :

Cancers

Abbreviated title :

Cancers (Basel)

Volume number :

12

Pages :

1992

Publication date :

2020-07-21

ISSN :

2072-6694

Keyword(s) :

COVID-19
clonal hematopoiesis
CHIP
sequencing
DNMT3A
TET2
SARS-CoV-2

HAL domain(s) :

Sciences du Vivant [q-bio]

English abstract : [en]

Advanced age or preexisting comorbidities have been characterized as risk factors for severe coronavirus disease 2019 (COVID-19) cases requiring hospitalization and intensive care. In recent years, clonal hematopoiesis ...
Show more >Advanced age or preexisting comorbidities have been characterized as risk factors for severe coronavirus disease 2019 (COVID-19) cases requiring hospitalization and intensive care. In recent years, clonal hematopoiesis (CH) of indeterminate potential (CHIP) has emerged as a risk factor for chronic inflammatory background and subsequent aging-associated diseases. The purpose of this study was to identify biological factors (particularly leukocyte subtypes and inflammatory markers) associated with a risk of clinical deterioration (i.e., orotracheal intubation (OTI)) and to determine whether CH was likely to influence clinical and biological behavior in patients with severe COVID-19 requiring hospitalization. Here, we describe clinical and biological features, including the screening of CHIP mutants in a well-annotated cohort of 122 hospitalized patients with a laboratory-confirmed diagnosis of COVID-19 (55% requiring OTI). We showed that elevated white blood cell counts, especially neutrophils and high C-reactive protein (CRP) levels at admission, were associated with an increased requirement of OTI. We noticed a high prevalence of CH (25%, 38%, 56%, and 82% of patients aged <60 years, 60-70 years, 70-80 years, and >80 years) compared to a retrospective cohort of patients free of hematological malignancy explored with the same pipelines (10%, 21%, 37%, and 44%). However, the existence of CH did not significantly impact clinical outcome, including OTI or death, and did not correlate with other laboratory findings.Show less >

Language :

Anglais

Audience :

Internationale

Popular science :

Non

Administrative institution(s) :

CHU Lille
CNRS
Inserm
Institut Pasteur de Lille
Université de Lille

Collections :

• Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286
• Miniaturisation pour la Synthèse, l'Analyse et la Protéomique (MSAP) - USR 3290
• Récepteurs nucléaires, Maladies Cardiovasculaires et Diabète (EGID) - U1011
• Unité de Glycobiologie Structurale et Fonctionnelle (UGSF) - UMR 8576

Submission date :

2021-07-06T12:47:34Z
2022-11-16T08:56:51Z